deltatrials
Completed PHASE2 NCT01382901

Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

A Phase 2a Study Evaluating the Efficacy and Safety of a Novel Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

Sponsor: American Regent, Inc.

Conditions Restless Legs Syndrome (RLS)
Interventions Ferric Carboxymaltose (FCM) Placebo
Updated 9 times since 2017 Last updated: Jan 22, 2018 Started: Mar 31, 2006 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

This PHASE2 trial investigates Restless Legs Syndrome (RLS) and is currently completed. American Regent, Inc. leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Feb 2019 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jun 2018 — Feb 2019 [monthly]

    Completed PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • American Regent, Inc.
Data source: American Regent, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.